Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: A proof of concept study

Heart

Volumn 95, Issue 16, 2009, Pages 1315-1319

  Chen, H H ^a   Martin, F L ^a   Gibbons, R J ^a   Schirger, J A ^a   Wright, R S ^a   Schears, R M ^a   Redfield, M M ^a   Simari, R D ^a   Lerman, A ^a   Cataliotti, A ^a   Burnett Jr , J C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CYCLIC GMP; IRBESARTAN; LISINOPRIL; METOPROLOL; METOPROLOL SUCCINATE; NESIRITIDE;

ACUTE HEART INFARCTION; ADULT; ALDOSTERONE BLOOD LEVEL; ANTERIOR ACUTE MYOCARDIAL INFARCTION; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION; STANDARD; UREA NITROGEN BLOOD LEVEL;

ALDOSTERONE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RECOMBINANT PROTEINS; STROKE VOLUME; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 68049144936     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.153916     Document Type: Article

References (22)

1. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-407.
2. Michaels AD, Klein A, Madden JA, et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697-701.
3. Lainchbury JG, Burnett JC Jr, Meyer D, et al. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000;278:H33-40.
4. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-7.
5. Yamahara K, Itoh H, Chun TH, et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 2003;100:3404-9.
6. Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-61.
7. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-34.
8. Kato T, Muraski J, Chen Y, et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005;115:2716-30.
9. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370:1483-93.
10. Hillock RJ, Frampton CM, Yandle TG, et al. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008;94:617-22.
11. Chen HH, Sundt TM, Cook DJ, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 2007;116(Suppl):I134-8.
12. Riter H, Redfield MM, Burnett JC, et al. Non-hypotensive low dose nesiritide has differential renal effects compared to standard dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006;47:2334-5.
13. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37:1820-6.
14. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
15. Clements IP, Brown ML, Smith HC. Radionuclide measurement of left ventricular volume. Mayo Clin Proc 1981;56:733-9.
16. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004;109:1680-5.
17. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
18. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:3009-17.
19. D'Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003;284:H1592-600.
20. Franco V, Chen YF, Oparil S, et al. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 2004;44:746-50.
21. Kasama S, Toyama T, Hatori T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007;49:667-74.
22. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.